Eli Lilly (LLY) has announced plans to spend $6B to construct a facility to produce active pharmaceutical ingredients in Huntsville, Ala.
The pharma said one of the drugs to be manufactured there is orforglipron, its oral GLP-1 candidate for obesity. The company is expected to submit an application for the candidate to the US FDA and other global regulatory agencies by the end of the month.
Once operational in 2032, the plant is expected to employ 450 individuals. Construction personnel will number around 3,000.
Earlier in 2025, Lilly pledged to construct four new API sites in the US. Two other ones have already been announced in Virginia and Texas.
